Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
So what: The deal is expected to close in Q2 and values ATMI at $1.15 billion, or roughly $850 million net of cash acquired including $170 million in net proceeds from the recent sale of ATMI's LifeSciences business to Pall.
Perhaps best of all for Entegris shareholders, the acquisition is expected to result in annualized cost savings of $30 million, will be immediately accretive to adjusted earnings per share, and should result in a stronger balance sheet to enable faster repayment of the company's debt.
Now what: This in mind, ATMI shareholders can't expect much more upside considering shares closed today at $33.79 per share, or only pennies below the $34-per-share acquisition price. As a result, I think it's time for ATMI shareholders to take profits and put their money to work elsewhere.
Here are some options
ATMI shareholders could simply turn around and buy shares of Entegris, but keep in mind there's also risk involved since the acquisition isn't a done deal just yet.
But if you'd like some alternatives, you're in luck!
Consider the investing expertise of Motley Fool co-founder David Gardner, who has proved skeptics wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
Steve Symington and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.